Bioventus (BVS) Competitors $7.04 -0.18 (-2.49%) Closing price 04:00 PM EasternExtended Trading$7.00 -0.04 (-0.57%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BVS vs. LQDA, PRCT, LMAT, AORT, EYE, ENOV, CNMD, NVCR, SSII, and ESTAShould you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include Liquidia Technologies (LQDA), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), NovoCure (NVCR), SS Innovations International (SSII), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry. Bioventus vs. Its Competitors Liquidia Technologies PROCEPT BioRobotics LeMaitre Vascular Artivion National Vision Enovis CONMED NovoCure SS Innovations International Establishment Labs Liquidia Technologies (NASDAQ:LQDA) and Bioventus (NYSE:BVS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Which has more risk & volatility, LQDA or BVS? Liquidia Technologies has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Does the media prefer LQDA or BVS? In the previous week, Liquidia Technologies had 10 more articles in the media than Bioventus. MarketBeat recorded 17 mentions for Liquidia Technologies and 7 mentions for Bioventus. Bioventus' average media sentiment score of 1.48 beat Liquidia Technologies' score of 0.52 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia Technologies 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate LQDA or BVS? Liquidia Technologies currently has a consensus target price of $32.11, suggesting a potential upside of 9.89%. Bioventus has a consensus target price of $13.75, suggesting a potential upside of 95.31%. Given Bioventus' higher probable upside, analysts plainly believe Bioventus is more favorable than Liquidia Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liquidia Technologies 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has stronger earnings & valuation, LQDA or BVS? Liquidia Technologies has higher earnings, but lower revenue than Bioventus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLiquidia Technologies$14M179.68-$130.39M-$1.70-17.19Bioventus$564.14M1.03-$156.23MN/AN/A Is LQDA or BVS more profitable? Bioventus has a net margin of -7.11% compared to Liquidia Technologies' net margin of -732.17%. Bioventus' return on equity of 15.61% beat Liquidia Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Liquidia Technologies-732.17% -232.96% -60.81% Bioventus -7.11%15.61%4.01% Do institutionals and insiders have more ownership in LQDA or BVS? 64.5% of Liquidia Technologies shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 30.1% of Liquidia Technologies shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryBioventus beats Liquidia Technologies on 9 of the 16 factors compared between the two stocks. Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BVS vs. The Competition Export to ExcelMetricBioventusSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$582.06M$81.28M$5.75B$21.15BDividend YieldN/AN/A6.66%3.51%P/E Ratio-11.5412.0382.4429.10Price / Sales1.03106.65530.5947.93Price / Cash12.5818.4125.7018.29Price / Book2.519.1410.645.30Net Income-$156.23M-$26.48M$3.28B$998.51M7 Day Performance-6.01%0.50%-0.08%-0.57%1 Month Performance13.92%9.68%10.35%6.43%1 Year Performance-29.53%83.30%48.99%13.75% Bioventus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BVSBioventus3.3552 of 5 stars$7.04-2.5%$13.75+95.3%-28.2%$582.06M$564.14M-11.541,200News CoverageLQDALiquidia Technologies2.645 of 5 stars$26.25-2.2%$32.11+22.3%+200.5%$2.31B$14M-15.4450Trending NewsInsider TradeOptions VolumePRCTPROCEPT BioRobotics3.6623 of 5 stars$39.31-4.7%$74.88+90.5%-49.9%$2.29B$224.50M-25.36430News CoveragePositive NewsAnalyst UpgradeLMATLeMaitre Vascular3.018 of 5 stars$97.60-2.7%$97.60+5.2%$2.27B$219.86M47.38490Positive NewsAORTArtivion3.3035 of 5 stars$43.53-2.9%$40.63-6.7%+60.9%$2.12B$388.54M-103.641,600EYENational Vision3.6049 of 5 stars$23.93-3.6%$24.73+3.3%+107.8%$1.97B$1.82B-132.9413,411Positive NewsENOVEnovis4.2698 of 5 stars$30.98-1.5%$51.00+64.6%-33.7%$1.80B$2.11B-2.177,367Positive NewsCNMDCONMED4.5945 of 5 stars$54.35-2.6%$59.80+10.0%-27.0%$1.73B$1.33B15.403,900Positive NewsNVCRNovoCure3.9834 of 5 stars$11.70-5.9%$28.79+146.0%-37.3%$1.39B$605.22M-7.501,488News CoverageSSIISS Innovations InternationalN/A$6.98-0.1%N/AN/A$1.35B$20.65M0.004ESTAEstablishment Labs2.0863 of 5 stars$40.66-6.8%$56.50+39.0%-12.0%$1.26B$166.02M-13.331,018News Coverage Related Companies and Tools Related Companies Liquidia Technologies Alternatives PROCEPT BioRobotics Alternatives LeMaitre Vascular Alternatives Artivion Alternatives National Vision Alternatives Enovis Alternatives CONMED Alternatives NovoCure Alternatives SS Innovations International Alternatives Establishment Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BVS) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
